324 related articles for article (PubMed ID: 27040343)
21. Substitution of linoleic acid with α-linolenic acid or long chain n-3 polyunsaturated fatty acid prevents Western diet induced nonalcoholic steatohepatitis.
Jeyapal S; Kona SR; Mullapudi SV; Putcha UK; Gurumurthy P; Ibrahim A
Sci Rep; 2018 Jul; 8(1):10953. PubMed ID: 30026586
[TBL] [Abstract][Full Text] [Related]
22. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Caldwell S
Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
[TBL] [Abstract][Full Text] [Related]
23. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.
Di Minno MN; Russolillo A; Lupoli R; Ambrosino P; Di Minno A; Tarantino G
World J Gastroenterol; 2012 Nov; 18(41):5839-47. PubMed ID: 23139599
[TBL] [Abstract][Full Text] [Related]
24. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Manne V; Handa P; Kowdley KV
Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
[TBL] [Abstract][Full Text] [Related]
25. Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation.
Yang J; Fernández-Galilea M; Martínez-Fernández L; González-Muniesa P; Pérez-Chávez A; Martínez JA; Moreno-Aliaga MJ
Nutrients; 2019 Apr; 11(4):. PubMed ID: 31003450
[TBL] [Abstract][Full Text] [Related]
26. Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice.
Bae JS; Park JM; Lee J; Oh BC; Jang SH; Lee YB; Han YM; Ock CY; Cha JY; Hahm KB
Metabolism; 2017 Jan; 66():32-44. PubMed ID: 27923447
[TBL] [Abstract][Full Text] [Related]
27. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids.
de Castro GS; Calder PC
Clin Nutr; 2018 Feb; 37(1):37-55. PubMed ID: 28139281
[TBL] [Abstract][Full Text] [Related]
28. Influence of the nutritional status and oxidative stress in the desaturation and elongation of n-3 and n-6 polyunsaturated fatty acids: Impact on non-alcoholic fatty liver disease.
Videla LA; Hernandez-Rodas MC; Metherel AH; Valenzuela R
Prostaglandins Leukot Essent Fatty Acids; 2022 Jun; 181():102441. PubMed ID: 35537354
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
[TBL] [Abstract][Full Text] [Related]
30. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.
Nobili V; Alisi A; Musso G; Scorletti E; Calder PC; Byrne CD
Crit Rev Clin Lab Sci; 2016; 53(2):106-20. PubMed ID: 26463349
[TBL] [Abstract][Full Text] [Related]
31. The Myristic Acid:Docosahexaenoic Acid Ratio Versus the n-6 Polyunsaturated Fatty Acid:n-3 Polyunsaturated Fatty Acid Ratio as Nonalcoholic Fatty Liver Disease Biomarkers.
Masetto Antunes M; Godoy G; Curi R; Vergílio Visentainer J; Barbosa Bazotte R
Metab Syndr Relat Disord; 2022 Mar; 20(2):69-78. PubMed ID: 34813379
[TBL] [Abstract][Full Text] [Related]
32. [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].
Чопей ІВ; Івачевська ВВ; Чубірко КІ; Гряділь ТІ; Гечко ММ
Wiad Lek; 2017; 70(2):169-173. PubMed ID: 28511152
[TBL] [Abstract][Full Text] [Related]
33. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
34. A lipidomic analysis of nonalcoholic fatty liver disease.
Puri P; Baillie RA; Wiest MM; Mirshahi F; Choudhury J; Cheung O; Sargeant C; Contos MJ; Sanyal AJ
Hepatology; 2007 Oct; 46(4):1081-90. PubMed ID: 17654743
[TBL] [Abstract][Full Text] [Related]
35. Dietary lipids and NAFLD: suggestions for improved nutrition.
Molendi-Coste O; Legry V; Leclercq IA
Acta Gastroenterol Belg; 2010; 73(4):431-6. PubMed ID: 21299150
[TBL] [Abstract][Full Text] [Related]
36. The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease.
Monteiro J; Leslie M; Moghadasian MH; Arendt BM; Allard JP; Ma DW
Food Funct; 2014 Mar; 5(3):426-35. PubMed ID: 24496399
[TBL] [Abstract][Full Text] [Related]
37. Fatty liver: role of inflammation and fatty acid nutrition.
Byrne CD
Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):265-71. PubMed ID: 20189787
[TBL] [Abstract][Full Text] [Related]
38. Impairment of reproductive function in a male rat model of non-alcoholic fatty liver disease and beneficial effect of N-3 fatty acid supplementation.
Li Y; Liu L; Wang B; Xiong J; Li Q; Wang J; Chen D
Toxicol Lett; 2013 Oct; 222(2):224-32. PubMed ID: 23747427
[TBL] [Abstract][Full Text] [Related]
39. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
[TBL] [Abstract][Full Text] [Related]
40. Omega 3 - Omega 6: What is right for the liver?
El-Badry AM; Graf R; Clavien PA
J Hepatol; 2007 Nov; 47(5):718-25. PubMed ID: 17869370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
